Remus PharmaceuticalsNSE:REMUS -1.02%55 EBITDA Margin % is 7.40% as of Mar. 2026, which is 21% below its 10-year median of 9.41. GuruFocus rates NSE:REMUS with a GF Score™ of 55/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 119 Medical Distribution companies, Remus Pharmaceuticals ranks better than 63.03% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Remus Pharmaceuticals EBITDA Margin % Related Terms
Remus Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:REMUS vs MCK, COR, CAH: EBITDA Margin % Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals EBITDA Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Remus Pharmaceuticals (NSE:REMUS) has a EBITDA Margin % of 7.40% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Remus Pharmaceuticals and its competitors. This is 21% below median its historical median of 9.41. Over the past decade, Remus Pharmaceuticals' EBITDA Margin % has ranged from 7.43 to 19.34. According to the industry distribution chart, Remus Pharmaceuticals ranks #44 out of 119 companies in the Medical Distribution industry, placing it in the top 37%.
Is Remus Pharmaceuticals' EBITDA Margin % too high?
Remus Pharmaceuticals' current EBITDA Margin % of 7.40% is 21% below median its 10-year median of 9.41. Over the past 10 years, this metric has ranged from a low of 7.43 to a high of 19.34. The Medical Distribution industry median EBITDA Margin % is 4.31. Remus Pharmaceuticals' value of 7.40% is 71.7% above this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #44 out of 119 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Remus Pharmaceuticals has a GF Score™ of 55/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' EBITDA Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #44 out of 119 companies for EBITDA Margin %. This puts Remus Pharmaceuticals in the upper half of its industry. The industry median EBITDA Margin % is 4.31. Remus Pharmaceuticals' value of 7.40% is 71.7% above this benchmark. Historically, Remus Pharmaceuticals' own EBITDA Margin % has ranged from 7.43 to 19.34 over the past decade. While the company's 10-year median is 9.41 vs. the industry median of 4.31, Remus Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Distribution company?
The median EBITDA Margin % among Medical Distribution companies is 4.31, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current EBITDA Margin % of 7.40% is 71.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median EBITDA Margin % is 4.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current EBITDA Margin % is 7.40%, which is 21% below median its own 10-year median of 9.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹793.70 — trading 61.7% below its estimated fair value. The current EBITDA Margin % is 7.40%, which is 21% below median its 10-year median of 9.41 and 71.7% above the Medical Distribution industry median of 4.31. Remus Pharmaceuticals' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current EBITDA Margin % is 7.40% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹793.70 is trading 61.7% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
EBITDA Margin %: 7.40% (21% below median its 10-year median of 9.41)
GF Value™: ₹2,071.36 vs. price of ₹793.70 (61.7% below fair value)
Industry Position: 71.7% above the Medical Distribution median (#44 of 119)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
55GF Score
Get the complete analysis for NSE:REMUS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
